Department of Neurosurgery, University of Michigan, Ann Arbor, Michigan.
Neurosurg Focus. 2017 Nov;43(5):E20. doi: 10.3171/2017.8.FOCUS17428.
OBJECTIVE Spinal cord injury (SCI) results in significant morbidity and mortality. Improving neurological recovery by reducing secondary injury is a major principle in the management of SCI. To minimize secondary injury, blood pressure (BP) augmentation has been advocated. The objective of this study was to review the evidence behind BP management after SCI. METHODS This systematic review was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Using the PubMed database, the authors identified studies that investigated BP management after acute SCI. Information on BP goals, duration of BP management, vasopressor selection, and neurological outcomes were analyzed. RESULTS Eleven studies that met inclusion criteria were identified. Nine studies were retrospective, and 2 were single-cohort prospective investigations. Of the 9 retrospective studies, 7 reported a goal mean arterial pressure (MAP) of higher than 85 mm Hg. For the 2 prospective studies, the MAP goals were higher than 85 mm Hg and higher than 90 mm Hg. The duration of BP management varied from more than 24 hours to 7 days in 6 of the retrospective studies that reported the duration of treatment. In both prospective studies, the duration of treatment was 7 days. In the 2 prospective studies, neurological outcomes were stable to improved with BP management. The retrospective studies, however, were contradictory with regard to the correlation of BP management and outcomes. Dopamine, norepinephrine, and phenylephrine were the agents that were frequently used to augment BP. However, more complications have been associated with dopamine use than with the other vasopressors. CONCLUSIONS There are no high-quality data regarding optimal BP goals and duration in the management of acute SCI. Based on the highest level of evidence available from the 2 prospective studies, MAP goals of 85-90 mm Hg for a duration of 5-7 days should be considered. Norepinephrine for cervical and upper thoracic injuries and phenylephrine or norepinephrine for mid- to lower thoracic injuries should be considered.
目的
脊髓损伤(SCI)会导致显著的发病率和死亡率。通过减少继发性损伤来改善神经恢复是 SCI 治疗的主要原则。为了最大限度地减少继发性损伤,提倡增加血压(BP)。本研究的目的是回顾 SCI 后血压管理的证据。
方法
本系统评价遵循 PRISMA(系统评价和荟萃分析的首选报告项目)指南进行。作者使用 PubMed 数据库确定了调查急性 SCI 后血压管理的研究。分析了 BP 目标、BP 管理持续时间、血管加压药选择和神经学结果的信息。
结果
确定了符合纳入标准的 11 项研究。9 项研究为回顾性,2 项为单队列前瞻性研究。在 7 项回顾性研究中,有 7 项报告了高于 85mmHg 的平均动脉压(MAP)目标。对于 2 项前瞻性研究,MAP 目标高于 85mmHg 和高于 90mmHg。在 6 项报告治疗持续时间的回顾性研究中,BP 管理的持续时间从超过 24 小时到 7 天不等。在 2 项前瞻性研究中,治疗持续时间为 7 天。在这两项前瞻性研究中,BP 管理与结局稳定或改善。然而,回顾性研究在 BP 管理与结局的相关性方面存在矛盾。多巴胺、去甲肾上腺素和苯肾上腺素是经常用于增加 BP 的药物。然而,与其他血管加压药相比,多巴胺的使用与更多的并发症相关。
结论
关于急性 SCI 管理中最佳 BP 目标和持续时间,没有高质量的数据。基于 2 项前瞻性研究中可获得的最高证据水平,MAP 目标应为 85-90mmHg,持续 5-7 天。应考虑使用去甲肾上腺素治疗颈和上胸段损伤,以及使用苯肾上腺素或去甲肾上腺素治疗中至下胸段损伤。